All posts

Constellation Software is still too pricey, Industrial Alliance says

You try and find a picture of Constellation Software CEO Mark Leonard…

Despite first quarter results he describes as “solid” Industrial Alliance Securities analyst Blair Abernethy is still not ready to recommend investors jump into Constellation Software (Constellation Software Stock Quote, Chart, News: TSX:CSU).

On Wednesday, CSU reported its Q1, 2018 results. The company earned (U.S.) $82.54-million on revenue of $71-million, a topline that was up 29 per cent over the same period last year.

As a result of the quarter, Abernethy today maintained his “Hold” rating, but raised his one-year price target on Constellation Software from $825.00 to $850.00, implying a return of negative 5.5 per cent at the time of publication. The analyst explained the reasoning behind this action.

“We expect Constellation to continue to drive material revenue growth and steadily scale its operation over the next few years,” he explained. “Q1 demonstrated significantly more small deal closures than last year. We expect the pace of small deal to remain strong in 2018. However, a current stock price levels we are maintaining our Hold rating.”

Abernethy expects CSU will generate EBITDA of $808.7-million on revenue of $3.08-billion in fiscal 2018. In 2019, he thinks the company will produce EBITDA of $920.6-million on a topline of $3.49-billion.

Tagged with: csu
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Verano Holdings is undervalued, Haywood says

Haywood Capital Markets analyst Neal Gilmer says Verano Holdings (Verano Holdings Stock Quote, Chart, News, Analysts, Financials NEO:VRNO) is staying… [Read More]

2 days ago

Knight Therapeutics is a buy, Stifel says

Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News, Analysts, Financials TSXV:GUD) is continuing to build momentum, according to Stifel Nicolaus… [Read More]

2 days ago

Groupon wins price target raise at Roth

Roth Capital Partners has raised its price target on Groupon (Groupon Inc Stock Quote, Chart, News, Analysts, Financials NASDAQ:GRPN) to… [Read More]

2 days ago

Trulieve Cannabis is a buy, Beacon says

Trulieve Cannabis (Trulieve Cannabis Stock Quote, Chart, News, Analysts, Financials CSE:TRUL) delivered a strong start to fiscal 2025, beating high-end… [Read More]

2 days ago

Green Thumb Industries should be a core holding for cannabis investors, analyst says

Green Thumb Industries (Green Thumb Industries Stock Quote, Chart, News, Analysts, Financials CSE:GTII) delivered a steady first quarter and remains… [Read More]

2 days ago

5N Plus just delivered an “exceptional” quarter, this analyst says

5N Plus (5N Plus Stock Quote, Chart, News, Analysts, Financials TSX:VNP) blew past expectations in the first quarter of 2025,… [Read More]

3 days ago